Shots: The MAA is supported by P-III program which includes 9000+ patients globally and data from DOLOMITES study, results of which will be disclosed this year. Results of P-III program […]readmore
Tags : FibroGen
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s […]readmore
Shots: The approval is based on four P-III studies evaluating Evrenzo (20/50/100mg) in CKD anemic patients on dialysis in Japan, demonstrating increment in hemoglobin level and is well tolerated among […]readmore
Shots: The NMPA’s approval is based on P-III study result assessing Roxadustat vs PBO in non-dialysis-dependent (NDD) patients with CKD demonstrating improvement in hemoglobin levels with a mean change of […]readmore